You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtacrynic acid
Accession NumberDB00903  (APRD00251)
TypeSmall Molecule
GroupsApproved
DescriptionA compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. [PubChem]
Structure
Thumb
Synonyms
(2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
acide étacrynique
ácido etacrínico
acidum etacrynicum
Etacrinic acid
Etakrinic acid
Ethacryinic Acid
Ethacrynate
Ethacrynic acid
Methylenebutyrylphenoxyacetic acid
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Edecrintablet25 mgoralValeant Canada Lp Valeant Canada S.E.C.2004-10-15Not applicableCanada
Edecrintablet25 mg/1oralKAISER FOUNDATION HOSPITALS2013-01-10Not applicableUs
Edecrintablet25 mg/1oralAvera Mc Kennan Hospital2015-10-02Not applicableUs
Edecrintablet25 mg/1oralAton Pharma, Inc.1967-01-10Not applicableUs
Edecrin Tab 50mgtablet50 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1968-12-312004-03-04Canada
Ethacrynic Sodiumpowder, for solution50 mg/50mLintravenousOceanside Pharmaceuticals1967-01-10Not applicableUs
Sodium Edecrinpowder, for solution50 mg/50mLintravenousAton Pharma, Inc.1967-01-10Not applicableUs
Sodium Edecrinpowder for solution50 mgintravenousValeant Canada Lp Valeant Canada S.E.C.1968-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethacrynate Sodiuminjection, powder, for solution50 mg/50mLintravenousPar Pharmaceutical, Inc.2015-07-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CrinurylAssia
EdecrilMerck
EdecrinaNot Available
EndecrilNot Available
HidromedinNot Available
HydromedinMerck
MingitNot Available
OtacrilNot Available
ReomaxBioindustria
TaladrenMalesci
UregitNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ethacrynate sodium
ThumbNot applicableDBSALT001225
Categories
UNIIM5DP350VZV
CAS number58-54-8
WeightAverage: 303.138
Monoisotopic: 302.011264286
Chemical FormulaC13H12Cl2O4
InChI KeyInChIKey=AVOLMBLBETYQHX-UHFFFAOYSA-N
InChI
InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
IUPAC Name
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
SMILES
CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenoxyacetic acid derivatives
Direct ParentPhenoxyacetic acid derivatives
Alternative Parents
Substituents
  • Phenoxyacetate
  • Butyrophenone
  • Phenylpropene
  • Acetophenone
  • Aryl ketone
  • Phenol ether
  • 1,2-dichlorobenzene
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Alpha-branched alpha,beta-unsaturated-ketone
  • Aryl halide
  • Aryl chloride
  • Vinylogous halide
  • Alpha,beta-unsaturated ketone
  • Enone
  • Acryloyl-group
  • Ketone
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.
PharmacodynamicsEthacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.
Mechanism of actionEthacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition.
Related Articles
AbsorptionOnset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.
Volume of distributionNot Available
Protein binding> 98%
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOverdosage may lead to excessive diuresis with electrolyte depletion.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ethacrynic Acid Action PathwayDrug actionSMP00097
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9591
Blood Brain Barrier-0.6921
Caco-2 permeable+0.5597
P-glycoprotein substrateSubstrate0.54
P-glycoprotein inhibitor INon-inhibitor0.5574
P-glycoprotein inhibitor IINon-inhibitor0.9828
Renal organic cation transporterNon-inhibitor0.9052
CYP450 2C9 substrateNon-substrate0.8508
CYP450 2D6 substrateNon-substrate0.8947
CYP450 3A4 substrateNon-substrate0.5262
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8384
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8344
BiodegradationReady biodegradable0.6545
Rat acute toxicity2.4505 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.9044
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aton pharma inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg/1
Tabletoral25 mg
Tabletoral50 mg
Injection, powder, for solutionintravenous50 mg/50mL
Powder for solutionintravenous50 mg
Powder, for solutionintravenous50 mg/50mL
Prices
Unit descriptionCostUnit
Sodium edecrin 50 mg vial527.4USD vial
Edecrin sodium 50 mg vial114.0USD vial
Ethacrynic acid 100% powder26.4USD g
Edecrin 25 mg tablet3.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point118.5-120.5Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.
logP3.3Not Available
pKa3.5MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.0194 mg/mLALOGPS
logP3.42ALOGPS
logP3.66ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)2.8ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity72.22 m3·mol-1ChemAxon
Polarizability28.57 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck
& co., Inc.

General ReferencesNot Available
External Links
ATC CodesC03CC01
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (75.2 KB)
MSDSDownload (74 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Etacrynic acid.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Etacrynic acid.
AcebutololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.
AceclofenacAceclofenac may decrease the diuretic activities of Etacrynic acid.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Etacrynic acid.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Etacrynic acid.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etacrynic acid.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Etacrynic acid.
AdapaleneAdapalene may decrease the diuretic activities of Etacrynic acid.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Etacrynic acid.
AlclometasoneAlclometasone may increase the hypokalemic activities of Etacrynic acid.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.
AldosteroneAldosterone may increase the hypokalemic activities of Etacrynic acid.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid.
AliskirenThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.
AllopurinolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Etacrynic acid.
AmcinonideAmcinonide may increase the hypokalemic activities of Etacrynic acid.
AmikacinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amikacin.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Etacrynic acid.
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Etacrynic acid.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.
AmobarbitalAmobarbital may increase the hypotensive activities of Etacrynic acid.
Amyl NitriteThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the diuretic activities of Etacrynic acid.
ApraclonidineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apraclonidine.
ApremilastApremilast may decrease the diuretic activities of Etacrynic acid.
ArbutamineArbutamine may increase the hypokalemic activities of Etacrynic acid.
ArformoterolArformoterol may increase the hypokalemic activities of Etacrynic acid.
AripiprazoleAripiprazole may increase the hypotensive activities of Etacrynic acid.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.
AzapropazoneAzapropazone may decrease the diuretic activities of Etacrynic acid.
AzelastineAzelastine may decrease the diuretic activities of Etacrynic acid.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the diuretic activities of Etacrynic acid.
BambuterolBambuterol may increase the hypokalemic activities of Etacrynic acid.
BarbitalBarbital may increase the hypotensive activities of Etacrynic acid.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etacrynic acid.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Etacrynic acid.
BetamethasoneBetamethasone may increase the hypokalemic activities of Etacrynic acid.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Etacrynic acid.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Etacrynic acid.
BretyliumThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etacrynic acid.
BromfenacBromfenac may decrease the diuretic activities of Etacrynic acid.
BudesonideBudesonide may increase the hypokalemic activities of Etacrynic acid.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Etacrynic acid.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Etacrynic acid.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etacrynic acid.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etacrynic acid.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Etacrynic acid.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etacrynic acid.
CandoxatrilEtacrynic acid may increase the hypotensive activities of Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Etacrynic acid.
CarprofenCarprofen may decrease the diuretic activities of Etacrynic acid.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.
CarvedilolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.
CastanospermineCastanospermine may decrease the diuretic activities of Etacrynic acid.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Etacrynic acid.
CelecoxibCelecoxib may decrease the diuretic activities of Etacrynic acid.
CeliprololCeliprolol may increase the hypokalemic activities of Etacrynic acid.
ChloroquineChloroquine may decrease the diuretic activities of Etacrynic acid.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.
CholestyramineCholestyramine can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Etacrynic acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etacrynic acid.
CilazaprilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.
CisplatinEtacrynic acid may increase the nephrotoxic activities of Cisplatin.
ClenbuterolClenbuterol may increase the hypokalemic activities of Etacrynic acid.
ClevidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Etacrynic acid.
ClocortoloneClocortolone may increase the hypokalemic activities of Etacrynic acid.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.
ClonixinClonixin may decrease the diuretic activities of Etacrynic acid.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etacrynic acid.
ColesevelamColesevelam can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Etacrynic acid.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.
D-LimoneneD-Limonene may decrease the diuretic activities of Etacrynic acid.
DapagliflozinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.
DaunorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Daunorubicin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Etacrynic acid.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Etacrynic acid.
DeslanosideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Etacrynic acid.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Etacrynic acid.
DexamethasoneDexamethasone may increase the hypokalemic activities of Etacrynic acid.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Etacrynic acid.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etacrynic acid.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etacrynic acid.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Etacrynic acid.
DiclofenacDiclofenac may decrease the diuretic activities of Etacrynic acid.
DiclofenamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diclofenamide.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Etacrynic acid.
DiflorasoneDiflorasone may increase the hypokalemic activities of Etacrynic acid.
DiflunisalDiflunisal may decrease the diuretic activities of Etacrynic acid.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Etacrynic acid.
DifluprednateDifluprednate may increase the hypokalemic activities of Etacrynic acid.
DigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etacrynic acid.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dihydrostreptomycin.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Etacrynic acid.
DinutuximabThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid.
DipivefrinDipivefrin may increase the hypokalemic activities of Etacrynic acid.
DipyridamoleThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Etacrynic acid.
DofetilideEtacrynic acid may increase the QTc-prolonging activities of Dofetilide.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.
DoxorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Doxorubicin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Etacrynic acid.
DroxicamDroxicam may decrease the diuretic activities of Etacrynic acid.
DroxidopaDroxidopa may increase the hypokalemic activities of Etacrynic acid.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etacrynic acid.
DuloxetineEtacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etacrynic acid.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Etacrynic acid.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etacrynic acid.
EnalaprilatEtacrynic acid may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Etacrynic acid.
EpinephrineEpinephrine may increase the hypokalemic activities of Etacrynic acid.
EpirizoleEpirizole may decrease the diuretic activities of Etacrynic acid.
EpirubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Epirubicin.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.
EquileninEquilenin may increase the hypokalemic activities of Etacrynic acid.
EquilinEquilin may increase the hypokalemic activities of Etacrynic acid.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.
EstroneEstrone may increase the hypokalemic activities of Etacrynic acid.
EtanerceptEtanercept may decrease the diuretic activities of Etacrynic acid.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etacrynic acid.
EtodolacEtodolac may decrease the diuretic activities of Etacrynic acid.
EtofenamateEtofenamate may decrease the diuretic activities of Etacrynic acid.
EtoricoxibEtoricoxib may decrease the diuretic activities of Etacrynic acid.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Etacrynic acid.
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Etacrynic acid.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Etacrynic acid.
exisulindexisulind may decrease the diuretic activities of Etacrynic acid.
FelodipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.
FenbufenFenbufen may decrease the diuretic activities of Etacrynic acid.
FenoprofenFenoprofen may decrease the diuretic activities of Etacrynic acid.
FenoterolFenoterol may increase the hypokalemic activities of Etacrynic acid.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.
FloctafenineFloctafenine may decrease the diuretic activities of Etacrynic acid.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Etacrynic acid.
FlumethasoneFlumethasone may increase the hypokalemic activities of Etacrynic acid.
FlunisolideFlunisolide may increase the hypokalemic activities of Etacrynic acid.
FlunixinFlunixin may decrease the diuretic activities of Etacrynic acid.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.
FluocinonideFluocinonide may increase the hypokalemic activities of Etacrynic acid.
FluocortoloneFluocortolone may increase the hypokalemic activities of Etacrynic acid.
FluorometholoneFluorometholone may increase the hypokalemic activities of Etacrynic acid.
FluprednideneFluprednidene may increase the hypokalemic activities of Etacrynic acid.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Etacrynic acid.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Etacrynic acid.
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Etacrynic acid.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Etacrynic acid.
FormoterolFormoterol may increase the hypokalemic activities of Etacrynic acid.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Etacrynic acid.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etacrynic acid.
FosphenytoinFosphenytoin may decrease the diuretic activities of Etacrynic acid.
FramycetinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Framycetin.
FurosemideFurosemide may increase the ototoxic activities of Etacrynic acid.
FurosemideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Furosemide.
GentamicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gentamicin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Etacrynic acid.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Etacrynic acid.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Etacrynic acid.
GuanfacineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Etacrynic acid.
HexobarbitalHexobarbital may increase the hypotensive activities of Etacrynic acid.
HMPL-004HMPL-004 may decrease the diuretic activities of Etacrynic acid.
HydralazineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Etacrynic acid.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.
Hygromycin BThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hygromycin B.
IbuprofenIbuprofen may decrease the diuretic activities of Etacrynic acid.
IbuproxamIbuproxam may decrease the diuretic activities of Etacrynic acid.
IcatibantIcatibant may decrease the diuretic activities of Etacrynic acid.
IdarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Idarubicin.
IndacaterolIndacaterol may increase the hypokalemic activities of Etacrynic acid.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid.
IndomethacinIndomethacin may decrease the diuretic activities of Etacrynic acid.
IndoprofenIndoprofen may decrease the diuretic activities of Etacrynic acid.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Etacrynic acid.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Etacrynic acid.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etacrynic acid.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Etacrynic acid.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etacrynic acid.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etacrynic acid.
IrbesartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.
IsoetarineIsoetarine may increase the hypokalemic activities of Etacrynic acid.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Etacrynic acid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Etacrynic acid.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the diuretic activities of Etacrynic acid.
IsoxsuprineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid.
IvabradineEtacrynic acid may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Kanamycin.
KebuzoneKebuzone may decrease the diuretic activities of Etacrynic acid.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etacrynic acid.
KetoprofenKetoprofen may decrease the diuretic activities of Etacrynic acid.
KetorolacKetorolac may decrease the diuretic activities of Etacrynic acid.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.
LeflunomideLeflunomide may decrease the diuretic activities of Etacrynic acid.
LevobunololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levobunolol.
LevodopaEtacrynic acid may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etacrynic acid.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etacrynic acid.
LicoriceLicorice may increase the hypokalemic activities of Etacrynic acid.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Etacrynic acid.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Etacrynic acid.
LornoxicamLornoxicam may decrease the diuretic activities of Etacrynic acid.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.
LoxoprofenLoxoprofen may decrease the diuretic activities of Etacrynic acid.
LumiracoxibLumiracoxib may decrease the diuretic activities of Etacrynic acid.
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Etacrynic acid.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Etacrynic acid.
MasoprocolMasoprocol may decrease the diuretic activities of Etacrynic acid.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Etacrynic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Etacrynic acid.
Mefenamic acidMefenamic acid may decrease the diuretic activities of Etacrynic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Etacrynic acid.
MeloxicamMeloxicam may decrease the diuretic activities of Etacrynic acid.
MesalazineMesalazine may decrease the diuretic activities of Etacrynic acid.
MetamizoleMetamizole may decrease the diuretic activities of Etacrynic acid.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etacrynic acid.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Etacrynic acid.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid.
MethohexitalMethohexital may increase the hypotensive activities of Etacrynic acid.
MethotrexateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.
MethyldopaThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Etacrynic acid.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Etacrynic acid.
MetipranololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Etacrynic acid.
MetrizamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metrizamide.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Etacrynic acid.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Etacrynic acid.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Etacrynic acid.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etacrynic acid.
MometasoneMometasone may increase the hypokalemic activities of Etacrynic acid.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Etacrynic acid.
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Etacrynic acid.
NabumetoneNabumetone may decrease the diuretic activities of Etacrynic acid.
NadololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nadolol.
NaftifineNaftifine may decrease the diuretic activities of Etacrynic acid.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etacrynic acid.
NaproxenNaproxen may decrease the diuretic activities of Etacrynic acid.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Etacrynic acid.
NCX 4016NCX 4016 may decrease the diuretic activities of Etacrynic acid.
NebivololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.
NeomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neomycin.
NepafenacNepafenac may decrease the diuretic activities of Etacrynic acid.
NesiritideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nesiritide.
NetilmicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Netilmicin.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.
NicorandilNicorandil may increase the hypotensive activities of Etacrynic acid.
NifedipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Etacrynic acid.
NimesulideNimesulide may decrease the diuretic activities of Etacrynic acid.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Etacrynic acid.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Etacrynic acid.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Etacrynic acid.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etacrynic acid.
OlodaterolOlodaterol may increase the hypokalemic activities of Etacrynic acid.
OlopatadineOlopatadine may decrease the diuretic activities of Etacrynic acid.
OlsalazineOlsalazine may decrease the diuretic activities of Etacrynic acid.
OmapatrilatEtacrynic acid may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Etacrynic acid.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Etacrynic acid.
OrgoteinOrgotein may decrease the diuretic activities of Etacrynic acid.
OuabainThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.
OxaprozinOxaprozin may decrease the diuretic activities of Etacrynic acid.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etacrynic acid.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etacrynic acid.
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Etacrynic acid.
PapaverineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Etacrynic acid.
ParecoxibParecoxib may decrease the diuretic activities of Etacrynic acid.
ParomomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paromomycin.
PenbutololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.
PentobarbitalPentobarbital may increase the hypotensive activities of Etacrynic acid.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etacrynic acid.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etacrynic acid.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Etacrynic acid.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Etacrynic acid.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Etacrynic acid.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Etacrynic acid.
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Etacrynic acid.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Etacrynic acid.
PhenytoinPhenytoin may decrease the diuretic activities of Etacrynic acid.
PimecrolimusPimecrolimus may decrease the diuretic activities of Etacrynic acid.
PindololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.
PirbuterolPirbuterol may increase the hypokalemic activities of Etacrynic acid.
PirfenidonePirfenidone may decrease the diuretic activities of Etacrynic acid.
PiroxicamPiroxicam may decrease the diuretic activities of Etacrynic acid.
PlicamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Plicamycin.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Etacrynic acid.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Etacrynic acid.
PrednisolonePrednisolone may increase the hypokalemic activities of Etacrynic acid.
PrednisonePrednisone may increase the hypokalemic activities of Etacrynic acid.
PregnenolonePregnenolone may increase the hypokalemic activities of Etacrynic acid.
PrimidonePrimidone may increase the hypotensive activities of Etacrynic acid.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.
ProcaterolProcaterol may increase the hypokalemic activities of Etacrynic acid.
PropacetamolPropacetamol may decrease the diuretic activities of Etacrynic acid.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Etacrynic acid.
PTC299PTC299 may decrease the diuretic activities of Etacrynic acid.
PuromycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Puromycin.
QuetiapineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Etacrynic acid.
RescinnamineEtacrynic acid may increase the hypotensive activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etacrynic acid.
ResveratrolResveratrol may decrease the diuretic activities of Etacrynic acid.
RibostamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ribostamycin.
RimexoloneRimexolone may increase the hypokalemic activities of Etacrynic acid.
RiociguatThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Riociguat.
RisperidoneEtacrynic acid may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Etacrynic acid.
RofecoxibRofecoxib may decrease the diuretic activities of Etacrynic acid.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etacrynic acid.
SalbutamolSalbutamol may increase the hypokalemic activities of Etacrynic acid.
SalicylamideSalicylamide may decrease the diuretic activities of Etacrynic acid.
Salicylic acidSalicylic acid may decrease the diuretic activities of Etacrynic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Etacrynic acid.
SalsalateSalsalate may decrease the diuretic activities of Etacrynic acid.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etacrynic acid.
SecobarbitalSecobarbital may increase the hypotensive activities of Etacrynic acid.
SeratrodastSeratrodast may decrease the diuretic activities of Etacrynic acid.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etacrynic acid.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.
SpectinomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Spectinomycin.
SpiraprilEtacrynic acid may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.
SRT501SRT501 may decrease the diuretic activities of Etacrynic acid.
StreptomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptomycin.
StreptozocinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.
SulfasalazineSulfasalazine may decrease the diuretic activities of Etacrynic acid.
SulindacSulindac may decrease the diuretic activities of Etacrynic acid.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etacrynic acid.
SulpirideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.
SuprofenSuprofen may decrease the diuretic activities of Etacrynic acid.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid.
TelmisartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.
TemocaprilEtacrynic acid may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the diuretic activities of Etacrynic acid.
TepoxalinTepoxalin may decrease the diuretic activities of Etacrynic acid.
TerazosinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Etacrynic acid.
TeriflunomideTeriflunomide may decrease the diuretic activities of Etacrynic acid.
ThiamylalThiamylal may increase the hypotensive activities of Etacrynic acid.
ThiopentalThiopental may increase the hypotensive activities of Etacrynic acid.
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Etacrynic acid.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Etacrynic acid.
TixocortolTixocortol may increase the hypokalemic activities of Etacrynic acid.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.
TobramycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tobramycin.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Etacrynic acid.
TolmetinTolmetin may decrease the diuretic activities of Etacrynic acid.
TopiramateEtacrynic acid may increase the hypokalemic activities of Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid.
TranilastTranilast may decrease the diuretic activities of Etacrynic acid.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Etacrynic acid.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Etacrynic acid.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Etacrynic acid.
ValdecoxibValdecoxib may decrease the diuretic activities of Etacrynic acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.
VilanterolVilanterol may increase the hypokalemic activities of Etacrynic acid.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Etacrynic acid.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Etacrynic acid.
ZaltoprofenZaltoprofen may decrease the diuretic activities of Etacrynic acid.
ZileutonZileuton may decrease the diuretic activities of Etacrynic acid.
ZomepiracZomepirac may decrease the diuretic activities of Etacrynic acid.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Bowes TJ, Gupta RS: Induction of mitochondrial fusion by cysteine-alkylators ethacrynic acid and N-ethylmaleimide. J Cell Physiol. 2005 Mar;202(3):796-804. [PubMed:15389563 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Ronquist G, Agren GK: A Mg2+- and Ca2+-stimulated adenosine triphosphatase at the outer surface of Ehrlich ascites tumor cells. Cancer Res. 1975 Jun;35(6):1402-6. [PubMed:124205 ]
  2. Proverbio F, Condrescu-Guidi M, Whittembury G: Ouabain-insensitive Na+ stimulation of an Mg-2+ -dependent ATPase in kidney tissue. Biochim Biophys Acta. 1975 Jun 25;394(2):281-92. [PubMed:124600 ]
  3. Valdes RM, Huff MO, El-Masri MA, El-Mallakh RS: Effect of ethacrynic acid on sodium pump alpha isoforms in SH-SY5Y cells. Bipolar Disord. 2003 Apr;5(2):123-8. [PubMed:12680902 ]
  4. Kiil F, Sejersted OM: Analysis of energy metabolism and mechanism of loop diuretics in the thick ascending limb of Henle's loop in dog kidneys. Acta Physiol Scand. 2003 May;178(1):73-82. [PubMed:12713517 ]
  5. Schurek HJ, Aulbert E, Ebel H, Muller-Suur C: Influence of ouabain and ethacrynic acid on sodium transport and NaK-ATPase activity in the isolated perfused rat kidney. Curr Probl Clin Biochem. 1975;4:162-8. [PubMed:127690 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name:
GSTA2
Uniprot ID:
P09210
Molecular Weight:
25663.675 Da
References
  1. Depeille P, Cuq P, Passagne I, Evrard A, Vian L: Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer. 2005 Jul 25;93(2):216-23. [PubMed:15999103 ]
  2. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA: Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta. 1993 Jul 10;1164(2):173-8. [PubMed:8329448 ]
  3. Iersel ML, Ploemen JP, Struik I, van Amersfoort C, Keyzer AE, Schefferlie JG, van Bladeren PJ: Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact. 1996 Oct 21;102(2):117-32. [PubMed:8950226 ]
  4. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521 ]
  5. Morrow CS, Smitherman PK, Townsend AJ: Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol. 1998 Oct 15;56(8):1013-21. [PubMed:9776312 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Nanni B, Raffaelli A, Salvadori P: Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal. 1998 Oct;18(1-2):127-36. [PubMed:9863950 ]
  2. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]
  3. Fehske KJ, Muller WE: High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin. Pharmacology. 1986;32(4):208-13. [PubMed:3714803 ]
  4. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23